Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Radiotherapy plus Toripalimab for stage I/II extranodal nasal NK/T-cell lymphoma with poor chemotherapy response
ChiCTR2100045147Phase 2Recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- May 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of toripalimab in Extranodal natural killer/T-cell lymphoma, nasal type (ENKTL), sponsored by West China Hospital of Sichuan University. Primary endpoint: Complete response rate. Started May 2021; status: recruiting.
02
Drugs
toripalimab
03
Conditions
Extranodal natural killer/T-cell lymphoma, nasal type (ENKTL)
Beyond the preview
Go deeper on ChiCTR2100045147.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100045147.